苦参素胶囊对乙型肝炎后肝硬化患者高甲胎蛋白影响研究简

目的：探讨苦参素胶囊对乙型肝炎后肝硬化（LC）患者高甲胎蛋白（AFP）的影响。方法：选择54例乙型肝炎后肝硬化高AFP患者，临床排除原发性肝癌（HCC），数字法随机分为苦参素胶囊治疗组27例和对照组27例。治疗组、对照组常规给予恩替卡韦、安络化纤丸、阿托莫兰治疗，治疗组加用苦参素胶囊。治疗观察周期10个月，或以确诊原发性肝癌（HCC）为治疗终点。观察2组发生HCC的例数和症状变化，以及AFP、HA、LN、HBV-DNA变化。结果：①发生HCC的例数和症状体征变化：治疗组HCC发生率、肝区疼痛、肝脏肿大、肝区不适、腹胀发生率低于对照组，具有显著差异（P〈0．05）。②AFP、ALT、LN、HA、HBV—DNA变化：治疗组AFP、LN、HA、HBV—DNA低于对照组，具有显著差异（P〈0．05）。结论：对慢性乙肝LC高AFP患者动态监测AFP，对HCC早发现、早诊断、早治疗具有重要意义。苦参素对慢性乙肝后肝硬化高AFP患者发生HCC具有一定作用。

Study of Impacted Effects of High Alpha-Fetoprotein in Patients with Liver Cirrhosis of Hepatitis B by Marine Capsules

Objective ： To investigate the impacted effects of high alpha-fetoprotein （ AFP ） in patients with liver cirrhosis of hepatitis B by Marine Capsules. Methods ： A total of 54 patients with liver cirrhosis of hepatitis B were randomly divided to treatment group （ n=27 ） and control group （ n=27 ）. Both groups were given entecavir, Anluohuaxian Capsule and reduced glutathione, and the treatment group added Marine Capsules. The period of treatment was 10 months, and the diagnosis of primary hepatocellular carcinoma （ HCC ） was also regarded as the endpoint. And then, the incidence rate of HCC and symptoms change were observed, and AFP, HA, LN and HBV DNA were measured. Results ： ~ Incidence rate of HCC andsymptoms change： in treatment group, the incidence rates of HCC, liver pain and hepatomegaly were significantly decreased （ P〈0.05 ）. （~） Changes of AFP, ALT, LN, HA, HBV-DNA ： AFP, LN, HA and HBV-DNA in treatment group were obviously lower than those in control group （ P〈0.05 ）. Conclusions： Dynamic monitor of the AFP in patients with post-hepatitis B cirrhosis had important significance for early discovery, early diagnosis and early treatment on HCC. Marine had preventive effect on the incidence rate of HCC on high alpha-fetoprotein in patients with post-hepatitis B cirrhosis.